Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A clinically defined disease states with a largely unknown morphological background. Acute mast cell activation (MCA) is commonly seen in allergic reactions and often leads to the clinical signs and symptoms of anaphylaxis. Severe or even life‐threatening MCA may occur when the burden of mast cells is high and/or these cells are in an hyperactivated state. Mastocytosis may be associated with mast cell activation syndrome (MCAS).
Biomarker and diagnostic research for mast cell activation syndrome has been reported in the published literature.
2 clinical trials registered, 1 recruiting. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
172 publications have been identified in PubMed for mast cell activation syndrome. Kisho has analyzed 116 by research type. Research spans Review / Meta-Analysis (37%), Basic Science / Preclinical (22%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 43 |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 7:14 PM UTC
Genetic and Rare Diseases Info Center
Laboratory research | 25 | 22% |
Patient case studies | 18 | 16% |
Disease patterns and progression | 9 | 8% |
Testing and diagnosis research | 8 | 7% |
New treatment approaches | 6 | 5% |
Other research | 4 | 3% |
Clinical study results | 3 | 3% |
Ahn C (2026). [PMID: 41932754](https://pubmed.ncbi.nlm.nih.gov/41932754/). *Immunol Allergy Clin North Am*. [Review / Meta-Analysis]
Yet M (2026). [PMID: 41428252](https://pubmed.ncbi.nlm.nih.gov/41428252/). *Inflammopharmacology*. [Review / Meta-Analysis]
Weiss M (2026). [PMID: 42149735](https://pubmed.ncbi.nlm.nih.gov/42149735/). *Pediatr Allergy Immunol*. [Clinical Trial Publication]
Chow TG (2026). [PMID: 41932747](https://pubmed.ncbi.nlm.nih.gov/41932747/). *Immunol Allergy Clin North Am*. [Review / Meta-Analysis]
Savigamin C (2026). [PMID: 41668453](https://pubmed.ncbi.nlm.nih.gov/41668453/). *Ann Med*. [Diagnostic / Biomarker]
Carter MC (2026). [PMID: 41285204](https://pubmed.ncbi.nlm.nih.gov/41285204/). *J Allergy Clin Immunol Pract*. [Review / Meta-Analysis]
Therrien A (2026). [PMID: 40367491](https://pubmed.ncbi.nlm.nih.gov/40367491/). *Am J Gastroenterol*. [Basic Science / Preclinical]
Weiss N (2026). [PMID: 41700025](https://pubmed.ncbi.nlm.nih.gov/41700025/). *Ear Nose Throat J*. [Review / Meta-Analysis]
Kulin D (2026). [PMID: 41952073](https://pubmed.ncbi.nlm.nih.gov/41952073/). *Neurogastroenterol Motil*. [Review / Meta-Analysis]
Chu R (2026). [PMID: 28722853](https://pubmed.ncbi.nlm.nih.gov/28722853/). *Unknown Journal*. [Gene Therapy / Novel Therapeutics]
AI-curated news mentioning mast cell activation syndrome
Updated Jun 4, 2026
New insights into mast cell activation syndrome (MCAS) have emerged with the six-year update on the global consensus-2 diagnostic criteria. This progress aims to enhance diagnostic accuracy and patient management for those affected by this rare condition.